Understanding how Mycobacterium abscessus survives antibiotic treatment
Regulation of antibiotic tolerance in Mycobacterium abscessus by proteolytic signaling
This study is looking at how a type of bacteria called Mycobacterium abscessus can survive antibiotics, especially in older people and those with weakened immune systems, to help find new ways to treat infections more effectively.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11097298 on NIH RePORTER |
What this research studies
This research investigates the mechanisms that allow the bacteria Mycobacterium abscessus to tolerate antibiotics, which is particularly important for older and immunocompromised patients who are at higher risk for these infections. The study aims to identify specific proteins involved in this tolerance by using advanced techniques in proteomics. By understanding how these bacteria respond to antibiotic stress, the research seeks to uncover potential targets for new treatments that could improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults and immunocompromised individuals who are at risk for Mycobacterium abscessus infections.
Not a fit: Patients with infections caused by other types of bacteria that do not involve Mycobacterium abscessus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from difficult-to-treat bacterial infections.
How similar studies have performed: Previous research has shown success in understanding antibiotic resistance mechanisms in other bacterial infections, suggesting that this approach may yield valuable insights.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Penn, Bennett — University of California at Davis
- Study coordinator: Penn, Bennett
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.